Licensed vaccines against viral diseases generate antibodies that neutralize the infecting
virus and protect against infection or disease. Similarly, an effective vaccine against HIV-1 …

Recent efforts toward an HIV vaccine focus on inducing broadly neutralizing antibodies, but
eliciting both neutralizing antibodies (nAbs) and cellular responses may be superior. Here …

New studies have greatly contributed toward our understanding of the specificities mediating
autologous neutralization and highlighted potential vulnerabilities on transmitted viruses …

Identifying the viral epitopes targeted by broad neutralizing antibodies (NAbs) that
sometimes develop in human immunodeficiency virus type 1 (HIV-1)-infected subjects …

We previously showed that HIV-1 subtype C viruses elicit potent but highly type-specific
neutralizing antibodies (nAb) within the first year of infection. In order to determine the …

ABSTRACT A small proportion of HIV-infected individuals generate a neutralizing antibody
(NAb) response of exceptional magnitude and breadth. A detailed analysis of the critical …

Human immunodeficiency virus type 1 (HIV-1) entry is mediated by the interaction between
a variably glycosylated envelope glycoprotein (gp120) and host-cell receptors …

One aim for an HIV vaccine is to elicit neutralizing antibodies (Nab) that can limit replication
of genetically diverse viruses and prevent establishment of a new infection. Thus, identifying …

The early autologous neutralizing antibody response in human immunodeficiency virus type
1 (HIV-1) subtype C infections is often characterized by high titers, but the response is type …

Here we have identified HIV-1 B clade Envelope (Env) amino acid signatures from early in
infection that may be favored at transmission, as well as patterns of recurrent mutation in …